These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 23800320)

  • 1. Clinical manifestations in female carriers of mucopolysaccharidosis type II: a Spanish cross-sectional study.
    Guillén-Navarro E; Domingo-Jiménez MR; Alcalde-Martín C; Cancho-Candela R; Couce ML; Galán-Gómez E; Alonso-Luengo O
    Orphanet J Rare Dis; 2013 Jun; 8():92. PubMed ID: 23800320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucopolysaccharidosis type II in a female patient with a reciprocal X;9 translocation and skewed X chromosome inactivation.
    Lonardo F; Di Natale P; Lualdi S; Acquaviva F; Cuoco C; Scarano F; Maioli M; Pavone LM; Di Gregorio G; Filocamo M; Scarano G
    Am J Med Genet A; 2014 Oct; 164A(10):2627-32. PubMed ID: 25044788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular diagnosis of 65 families with mucopolysaccharidosis type II (Hunter syndrome) characterized by 16 novel mutations in the IDS gene: Genetic, pathological, and structural studies on iduronate-2-sulfatase.
    Kosuga M; Mashima R; Hirakiyama A; Fuji N; Kumagai T; Seo JH; Nikaido M; Saito S; Ohno K; Sakuraba H; Okuyama T
    Mol Genet Metab; 2016 Jul; 118(3):190-197. PubMed ID: 27246110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Female Hunter syndrome caused by a single mutation and familial XCI skewing: implications for other X-linked disorders.
    Kloska A; Jakóbkiewicz-Banecka J; Tylki-Szymańska A; Czartoryska B; Węgrzyn G
    Clin Genet; 2011 Nov; 80(5):459-65. PubMed ID: 21062272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are MPS II heterozygotes actually asymptomatic? A study based on clinical and biochemical data, X-inactivation analysis and imaging evaluations.
    de Camargo Pinto LL; Maluf SW; Leistner-Segal S; Zimmer da Silva C; Brusius-Facchin A; Burin MG; Brustolin S; Llerena J; Moraes L; Vedolin L; Schuch A; Giugliani R; Schwartz IV
    Am J Med Genet A; 2011 Jan; 155A(1):50-7. PubMed ID: 21204210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. iPS-derived neural stem cells for disease modeling and evaluation of therapeutics for mucopolysaccharidosis type II.
    Hong J; Cheng YS; Yang S; Swaroop M; Xu M; Beers J; Zou J; Huang W; Marugan JJ; Cai X; Zheng W
    Exp Cell Res; 2022 Mar; 412(1):113007. PubMed ID: 34990619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and biochemical studies in mucopolysaccharidosis type II carriers.
    Schwartz IVD; Pinto LLC; Breda G; Lima L; Ribeiro MG; Mota JG; Acosta AX; Correia P; Horovitz DDG; Porciuncula CGG; Lipinski-Figueiredo E; Fett-Conte AC; Oliveira Sobrinho RP; Norato DYJ; Paula AC; Kim CA; Duarte AR; Boy R; Leistner-Segal S; Burin MG; Giugliani R
    J Inherit Metab Dis; 2009 Dec; 32(6):732-738. PubMed ID: 19821143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer.
    Laoharawee K; Podetz-Pedersen KM; Nguyen TT; Evenstar LB; Kitto KF; Nan Z; Fairbanks CA; Low WC; Kozarsky KF; McIvor RS
    Hum Gene Ther; 2017 Aug; 28(8):626-638. PubMed ID: 28478695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucopolysaccharidosis type II (Hunter's syndrome) in Taiwan.
    Su PH; Hwu WL; Chiang SC; Chiu PC; Lin SJ; Shu SG; Wang TR
    J Formos Med Assoc; 1998 Mar; 97(3):186-90. PubMed ID: 9549269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A method for measuring disease-specific iduronic acid from the non-reducing end of glycosaminoglycan in mucopolysaccharidosis type II mice.
    Shimada Y; Wakabayashi T; Akiyama K; Hoshina H; Higuchi T; Kobayashi H; Eto Y; Ida H; Ohashi T
    Mol Genet Metab; 2016 Feb; 117(2):140-3. PubMed ID: 26051019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extension of the molecular analysis to the promoter region of the iduronate 2-sulfatase gene reveals genomic alterations in mucopolysaccharidosis type II patients with normal coding sequence.
    Brusius-Facchin AC; Abrahão L; Schwartz IV; Lourenço CM; Santos ES; Zanetti A; Tomanin R; Scarpa M; Giugliani R; Leistner-Segal S
    Gene; 2013 Sep; 526(2):150-4. PubMed ID: 23707223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome.
    Arguello A; Meisner R; Thomsen ER; Nguyen HN; Ravi R; Simms J; Lo I; Speckart J; Holtzman J; Gill TM; Chan D; Cheng Y; Chiu CL; Dugas JC; Fang M; Lopez IA; Solanoy H; Tsogtbaatar B; Zhu Y; Bhalla A; Henne KR; Henry AG; Delucchi A; Costanzo S; Harris JM; Diaz D; Scearce-Levie K; Sanchez PE
    JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case report: a rare case of Hunter syndrome (type II mucopolysaccharidosis) in a girl.
    Semyachkina AN; Voskoboeva EY; Zakharova EY; Nikolaeva EA; Kanivets IV; Kolotii AD; Baydakova GV; Kharabadze MN; Kuramagomedova RG; Melnikova NV
    BMC Med Genet; 2019 May; 20(1):66. PubMed ID: 31046699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucopolysaccharidosis type II: skeletal-muscle system involvement.
    Morini SR; Steiner CE; Gerson LB
    J Pediatr Orthop B; 2010 Jul; 19(4):313-7. PubMed ID: 20354449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mutational spectrum of hunter syndrome reveals correlation between biochemical and clinical profiles in Tunisian patients.
    Chkioua L; Grissa O; Leban N; Gribaa M; Boudabous H; Turkia HB; Ferchichi S; Tebib N; Laradi S
    BMC Med Genet; 2020 May; 21(1):111. PubMed ID: 32448126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Auditory characteristics and therapeutic effects of enzyme replacement in mouse model of the mucopolysaccharidosis (MPS) II.
    Hong SH; Chu H; Kim KR; Ko MH; Kwon SY; Moon IJ; Chung WH; Cho YS; Kim CH; Suh MW; Choi EW; Sohn YB; Park SW; Kim SH; Cho SY; Ko AR; Jin DK
    Am J Med Genet A; 2012 Sep; 158A(9):2131-8. PubMed ID: 22847837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. X-Chromosome Inactivation Analysis in Different Cell Types and Induced Pluripotent Stem Cells Elucidates the Disease Mechanism in a Rare Case of Mucopolysaccharidosis Type II in a Female.
    Řeboun M; Rybová J; Dobrovolný R; Včelák J; Veselková T; Štorkánová G; Mušálková D; Hřebíček M; Ledvinová J; Magner M; Zeman J; Pešková K; Dvořáková L
    Folia Biol (Praha); 2016; 62(2):82-9. PubMed ID: 27187040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients.
    Bhalla A; Ravi R; Fang M; Arguello A; Davis SS; Chiu CL; Blumenfeld JR; Nguyen HN; Earr TK; Wang J; Astarita G; Zhu Y; Fiore D; Scearce-Levie K; Diaz D; Cahan H; Troyer MD; Harris JM; Escolar ML
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
    Tanaka N; Kida S; Kinoshita M; Morimoto H; Shibasaki T; Tachibana K; Yamamoto R
    Mol Genet Metab; 2018 Sep; 125(1-2):53-58. PubMed ID: 30064964
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.